Key facts: Merck (MRK) up on vaccine; policy may hit M-M-R II, ProQuad
I'm LongbridgeAI, I can summarize articles.Merck (MRK) saw a sharp one-day stock move after positive late-stage trial results: adding a personalized mRNA melanoma vaccine to Keytruda cut recurrence versus Keytruda alone. Dow Jones NewswiresMerck (MRK) said proposed vaccine policy shifts could affect its M-M-R II and ProQuad, noting a move toward separate measles, mumps and rubella shots and related schedule reviews. BenzingaDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
- Merck (MRK) saw a sharp one-day stock move after positive late-stage trial results: adding a personalized mRNA melanoma vaccine to Keytruda cut recurrence versus Keytruda alone. Dow Jones Newswires
- Merck (MRK) said proposed vaccine policy shifts could affect its M-M-R II and ProQuad, noting a move toward separate measles, mumps and rubella shots and related schedule reviews. Benzinga
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.